welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
Avidity Biosciences Receives Investment from CureDuchenne
Avidity Biosciences, a privately held biotech company pioneering a new class of precision medicines based upon antibody-oligonucleotide conjugates, announced today that CureDuchenne has made an equity investment in the company. Funding will help to advance pre-clinical development of potential therapies to treat patients with Duchenne muscular dystrophy (DMD).
rareRelated
-
Single CRISPR Treatment Provides Long-Term Benefits in MiceResearchers at Duke University have show...
-
CureDuchenneCureDuchenne is recognized as the global...
-
A Randomized, Double-blind, Placebo-controlled Study of SRP-9001 for Duchenne Muscular Dystrophy (DMD)The purpose of this study is to evaluate...
-
CureDuchenne Ventures Commits $500,000 to 4D Molecular Therapeutics to Advance Next-Generation AAV Delivery of Gene ...CureDuchenne, a national venture phila...
-
Evox Therapeutics wins funding from Duchenne UK to explore exosome-mediated delivery of dystrophinEvox Therapeutics Ltd, a leading exosome...
-
The Gene-Edited Babies And CRISPR-Cas9 Controversy, ExplainedOutrage continues to grow over the news ...
-
Oral Ifetroban in Subjects With Duchenne Muscular DystrophyDuchenne muscular dystrophy (DMD) is a d...